New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
February 21, 2020 - Lundbeck announced the FDA approval of Vyepti (eptinezumab-jjmr), for the preventive treatment of migraine in adults.
Download PDF
Return to publications
